Compare Check Point Software Technologies Ltd (CHKP) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Check Point Software Technologies Ltd vs 10X Genomics Inc — how do they compare? Check Point Software Technologies Ltd trades at $128.7 (market cap $13.18B), while 10X Genomics Inc trades at $57.61 (market cap $7.61B). The key difference: Check Point Software Technologies Ltd is the larger of the two by market cap, and 10X Genomics Inc is trading nearer its 52-week high, Check Point Software Technologies Ltd nearer its low. Which is the better fit depends on your goals.
| CHKP | TXG | |
|---|---|---|
Market Cap | $13.18B | $7.61B |
Sector | Technology | Health |
52-Week High | $206.91 | $58.57 |
52-Week Low | $112.47 | $11.34 |
Enterprise Value | $12.88B | $7.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Check Point Software Technologies (CHKP) trades at $128.21, down 2.23% on the day, reflecting recent bearish pressure. The stock shows strong profitability with a net margin of 37.93% and has beaten earnings estimates for three consecutive quarters. Technical indicators signal a bearish trend, with the price near support at $128. Recent news highlights AI security growth potential and insider selling activity.
The outlook is mixed: valuation appears attractive with a P/E of 13.24, but growth challenges and margin pressures pose risks. Analyst consensus leans neutral with a $146.92 price target, suggesting cautious optimism for recovery driven by AI security demand, though competitive and execution risks remain.
TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.
Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Check Point Software Technologies Ltd
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
